Nuvalent (Nasdaq:NUVL) stock surged 39.11% after GSK agreed to buy the oncology biotech for $10.6 billion at $124 per share in cash.

Key Highlights

  • Nuvalent shares rose 39.11% to $123.10 on June 9.
  • GSK agreed to acquire Nuvalent for $124 per share in cash.
  • The deal strengthens GSK’s precision oncology pipeline, particularly in lung cancer.

Nuvalent, Inc. (NASDAQ:NUVL) surged 39.11% during the June 9 regular session, rising to $123.10 from a previous close of $88.49. The stock opened at $122.81 and traded between $122.80 and $123.62, with Volume of about 46.75 million shares.

The move followed GSK’s agreement to acquire Nuvalent in a $10.6 billion all-cash transaction. GSK will pay $124 per share, representing a 40% premium to Nuvalent’s prior closing price and a 26% premium to the 30-day volume-weighted average price.

The market reaction was straightforward. Nuvalent’s share price moved close to the Offer Price, reflecting investor expectation that the transaction could close on the announced terms.

Why GSK Is Buying Nuvalent

The Acquisition gives GSK a larger position in precision oncology, particularly in non-small cell lung cancer. Nuvalent is developing targeted therapies designed for patients with cancer-driving genetic alterations, including ROS1-positive and ALK-positive lung cancer.

Nuvalent’s lead late-stage Assets include zidesamtinib and neladalkib. GSK expects these medicines to strengthen its oncology Franchise and contribute to Revenue growth from 2027 if approved and successfully commercialized. Reuters reported that both drugs are viewed as potential multi-blockbuster products, with regulatory decisions expected later in 2026.

For GSK, the deal also addresses a strategic gap. The company has been rebuilding its cancer portfolio after returning to oncology in recent years. The Nuvalent transaction marks a major move under CEO Luke Miels and signals a willingness to use large-scale M&A to accelerate growth.

What the Deal Means for Nuvalent Investors

For Nuvalent shareholders, the stock’s rally largely reflects deal Economics. With the stock trading near $123 and the offer set at $124, the market is pricing in a high probability of completion while leaving a small spread for deal risk.

The transaction is expected to close in the third quarter, subject to regulatory approvals and customary closing conditions. GSK said it will fund the acquisition through cash and Debt facilities, and the deal is not expected to affect its current guidance or Credit rating.

The key risk for Nuvalent investors is no longer a standalone clinical valuation debate. It is whether the deal clears regulatory and closing hurdles. Until the transaction is completed, the stock may trade close to the offer price rather than on independent pipeline expectations.

Strategic Logic for GSK

GSK is paying a full price, but the strategic rationale is clear. Oncology remains a high-value therapeutic area where successful targeted medicines can generate durable revenue if clinical performance and regulatory execution are strong.

Nuvalent offers late-stage assets in genetically defined lung cancer markets, which can be attractive because precision oncology drugs may serve clear patient populations and command premium pricing. If the assets are approved, GSK could gain near-term launch opportunities rather than waiting many years for early-stage programs to mature.

The deal also comes as GSK seeks to strengthen future growth drivers. Reuters noted that the acquisition helps support GSK’s oncology expansion while the company prepares for future pressure from Patent expirations in other parts of its portfolio.

Why GSK Investors Were More Cautious

While Nuvalent shares rallied, GSK’s stock reaction was more cautious. Large acquisitions often raise questions around price discipline, integration risk and the probability that pipeline assets will achieve expected commercial value.

The market will watch whether GSK can convert Nuvalent’s clinical promise into approved products, reimbursement access and meaningful sales. Late-stage biotech assets still carry regulatory and execution risk. Even strong science does not guarantee approval, launch success or blockbuster revenue.

That is why the deal looks positive for Nuvalent holders but more complex for GSK shareholders.

Conclusion

Nuvalent’s 39.11% surge reflects GSK’s $10.6 billion cash acquisition offer, not a routine biotech rally. The $124-per-share bid places a clear valuation floor near the current stock price, assuming the deal closes as planned.

For Nuvalent investors, the focus now shifts to deal completion. For GSK, the acquisition is a major oncology bet that could strengthen its lung cancer pipeline and accelerate growth from 2027. The long-term success of the transaction will depend on regulatory approvals, clinical execution and whether Nuvalent’s late-stage therapies deliver commercial value.